THE SHORT ANSWER
Does Humana Cover Zepbound?
Humana's Own Plans Exclude Weight Loss; the Medicare Bridge Doesn't
Humana's own Medicare plans do not cover Zepbound for weight loss, and Humana no longer sells employer-group commercial medical plans (exit completed in 2025). On Humana's Medicare plans this isn't a prior authorization question: by federal law, basic Part D coverage excludes drugs used for weight loss, and Humana's plans don't cover them. But Humana Medicare Advantage (MA-PD) and Part D (PDP) members can use the Medicare GLP-1 Bridge, a separate CMS program outside the Part D benefit, which covers the Zepbound KwikPen for weight loss for $50 per monthly fill if they meet CMS's eligibility criteria and their prescriber gets prior authorization.
Unlike some insurers where coverage "varies by plan," Humana has been unusually clear: GLP-1 agonists will not be covered for weight loss by its MAPD/PDP plans themselves. Here's what this means for you:
- A weight-loss claim won't be approved by the plan—it's excluded, not a medical-necessity question
- Appealing is unlikely to help—you're fighting a plan exclusion, not a medical necessity denial
- Exceptions may exist for Type 2 diabetes (Mounjaro), sleep apnea (Medicare), or some Medicaid plans
- For weight loss on Medicare, use the Bridge—An E66 diagnosis code and a “SEND TO BRIDGE” note are recommended, not required; no Part D denial is needed first
Bottom line: If you have Humana Medicare and want Zepbound for weight loss, the Medicare GLP-1 Bridge (KwikPen only, if you meet its criteria) is your coverage pathway, not an appeal to Humana. Otherwise, explore self-pay options.
For a complete overview of getting Zepbound covered regardless of insurer, see our full coverage guide.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
WHAT IT ACTUALLY MEANS
Humana's Weight Loss Exclusion
Since June 2023, Humana has used a point-of-sale diagnosis code requirement (a "medically accepted indication" edit) to block off-label use of several diabetes drugs, such as Ozempic or Mounjaro for weight loss. Humana’s “medically accepted indication” edit applies to Ozempic, Rybelsus, Trulicity, Victoza, Mounjaro and a few other drugs, not Zepbound.[1] For Zepbound itself, the weight-loss block is the Part D exclusion described above.
How the Diagnosis Code Edit Works
When a pharmacy submits a claim for one of these drugs, Humana's system checks the ICD-10 diagnosis code. If the code isn't a medically accepted use (for example, an obesity code on a Mounjaro claim), the claim rejects at the pharmacy.
The edit is lifted if Humana's claims data or the submitted code shows an accepted use (such as type 2 diabetes); otherwise the prescriber can request prior authorization.[1]
Accepted vs. Rejected Diagnosis Codes
| ICD-10 Code | Diagnosis | Claim Result |
|---|---|---|
| E11.xx | Type 2 Diabetes Mellitus | Accepted use (claim can process) |
| E66.01, E66.09, E66.1 | Obesity/Overweight | Rejects (code 88) |
| Z68.x | BMI Codes | Rejects (code 88) |
Humana's Rejection Messages
When a claim for one of the listed drugs is rejected, the pharmacy sees one of these error codes:
- Reject Code 39: "ICD-10 is required"—no diagnosis code was submitted
- Reject Code 88: "Use is not medically accepted"—the obesity/weight loss code triggered the exclusion
Source: Humana's "Medically Accepted Indication Edit" notice, June 2023 (updated April 2024). The table shows how the edit treats the drugs on its list (such as Mounjaro); Zepbound is not on the list.[1]
WHERE ZEPBOUND MIGHT BE COVERED
Humana Plan Types
Coverage varies significantly by the type of Humana plan you have:
| Plan Type | Weight Loss | Diabetes/OSA | Key Notes |
|---|---|---|---|
| Commercial (Employer) | No longer offered | — | Humana no longer sells employer-group commercial medical plans (exit completed in 2025) |
| Medicare Advantage (MAPD) | Plan excludes; Bridge: $50 per monthly fill | Limited (OSA only) | Basic Part D coverage excludes weight-loss drugs; the Medicare GLP-1 Bridge can cover the Zepbound KwikPen outside Part D, with conditions |
| Medicare Part D (PDP) | Plan excludes; Bridge: $50 per monthly fill | Limited (OSA, with PA) | Same federal exclusion applies to the plan; PDP members can use the Bridge if they meet its criteria |
| Medicaid (varies by state) | Some states | Varies | Check your state; 13 states (as of January 2026) cover GLP-1s for obesity |
Sleep Apnea: A Potential Exception
OSA Coverage on Humana Medicare
Humana's Medicare policy covers Zepbound for obstructive sleep apnea (OSA) when its criteria are met, but NOT for weight loss alone. This is Part D coverage, separate from the Bridge. Humana's Zepbound pharmacy coverage policy (reviewed July 15, 2026) requires ALL of the following:[4]
- Moderate-to-severe OSA diagnosis (AHI ≥15 on polysomnogram or REI ≥15 on home sleep test)
- BMI ≥30 (obesity, as in the FDA label)
- Using Zepbound with lifestyle modifications (reduced-calorie diet + physical activity)
- NO diabetes diagnosis (type 1 or type 2)—this is an exclusion criterion
Use diagnosis code G47.33 for OSA as the primary diagnosis, with obesity as secondary.
How to Check Your Specific Plan
Call Script for Humana
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) covered on my plan's formulary?
- Is it covered for weight management, or only for diabetes/sleep apnea?
- What diagnosis codes are accepted for this medication?
- If it's not covered for weight loss, what are my options?"
UNDERSTAND YOUR OPTIONS
If Humana Denies Zepbound
Important: Plan Exclusions Rarely Overturn
If Humana denied your Zepbound because weight loss isn't a covered indication, an appeal is unlikely to succeed. You're fighting the plan's benefit structure, not a medical necessity decision. Save your energy for cases where appeals make sense.
Common Humana Denial Reasons
- "Plan exclusion" — Weight loss is not a covered indication
- "Missing diagnosis code" — for drugs on Humana's diagnosis-code edit (such as Mounjaro), the pharmacy didn't submit an ICD-10 code (resubmit, don't appeal)
- "Prior auth not obtained" — Medicaid plans that cover it may require PA before filling
- "Step therapy required" — Some plans require trying other drugs first
When an Appeal Makes Sense
- Medicaid PA denial — you meet criteria but were denied anyway
- OSA coverage dispute — Medicare denied despite valid sleep apnea diagnosis
- Wrong diagnosis code — your doctor listed the wrong indication
- Renewal denial — you showed ≥5% weight loss but were still denied
If your situation fits one of these, an appeal may be worth filing. Use Honest Care to build your appeal →
Humana Medicaid (Exception)
If you have Humana Healthy Horizons (Medicaid) in a state that covers GLP-1s for weight loss, prior authorization applies. 13 states (as of January 2026) cover GLP-1s for obesity under Medicaid.[3]
For complete prior auth preparation, see our Zepbound prior authorization guide →
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
YOUR OPTIONS
What If Humana Won't Cover Zepbound?
If you don't qualify for the Medicare GLP-1 Bridge, here are realistic alternatives:
| Option | Cost | Notes |
|---|---|---|
| LillyDirect | $299–$449/month | Cash pay via Zepbound Self Pay Journey; $299 (2.5mg), $399 (5mg), $449 (7.5-15mg)[7] |
| Walmart Pickup | LillyDirect self-pay price | LillyDirect self-pay vials with Walmart pharmacy pickup (launched November 2025; check LillyDirect for current availability)[8] |
| Telehealth + Cash Pay | Drug's self-pay price plus visit fees | Online prescribers can write a self-pay prescription; you still pay the drug's self-pay price |
| TrumpRx.gov | Same as LillyDirect | Launched February 5, 2026; TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price); no insurance needed |
| Foundayo | $149–$299/month | Eli Lilly's oral GLP-1 (FDA approved April 1, 2026)—no injections, may have different coverage |
| Alternative GLP-1s | Varies | Check if Wegovy, Saxenda, or Ozempic have different coverage |
Manufacturer Savings Card Won't Help
Lilly's Zepbound savings card is for commercial insurance only: Not for Medicare, Medicaid, TRICARE, VA or other government insurance. Since Humana now offers Medicare and Medicaid plans, the savings card can't be applied to reduce your cost.
For complete self-pay options, see our LillyDirect guide → or Zepbound cost overview →
HUMANA ZEPBOUND COVERAGE
Frequently Asked Questions
Not through Humana's own plans—but Humana Medicare members can use the Medicare GLP-1 Bridge. Humana's Medicare plans exclude weight loss as a covered indication for GLP-1 medications, and Humana no longer sells employer-group commercial medical plans (exit completed in 2025). A Zepbound claim for weight loss won't be approved because, by law, basic Part D coverage excludes drugs used for weight loss; this is an exclusion, so appeals are unlikely to succeed. The Medicare GLP-1 Bridge, a separate CMS program outside the Part D benefit, covers the Zepbound KwikPen for weight loss for $50 per monthly fill if you meet CMS eligibility criteria and your prescriber gets prior authorization.
Not Zepbound specifically—Zepbound is only FDA-approved for weight management and sleep apnea. However, Mounjaro (same drug, different brand) is approved for Type 2 diabetes and may be covered on Humana plans with prior authorization. Ask your doctor about Mounjaro if you have T2D.
Yes, with strict criteria. Per Humana's Zepbound pharmacy coverage policy (reviewed July 15, 2026), Humana Medicare covers Zepbound for OSA if you meet ALL of these: (1) moderate-to-severe OSA (AHI ≥15), (2) BMI ≥30, (3) using it with lifestyle modifications, and (4) you do NOT have type 1 or type 2 diabetes. Prior authorization is required. Use diagnosis code G47.33 as primary.
On a Humana Medicare plan, one likely reason is that Zepbound was prescribed for weight loss, which basic Part D coverage excludes by law (check whether you qualify for the Medicare GLP-1 Bridge instead); for sleep apnea, Zepbound needs prior authorization. Humana's diagnosis-code edit (since June 2023) applies to diabetes drugs such as Ozempic and Mounjaro, not Zepbound: a claim for those with an obesity code (E66.x) instead of diabetes (E11.x) rejects with "Reject Code 88: Use is not medically accepted."
You can, but it's unlikely to succeed for plan exclusions. If Humana denied coverage because weight loss isn't a covered indication, you're fighting the plan's benefit structure—not a medical necessity decision. Appeals are more effective for: Medicaid PA denials where you meet criteria, OSA coverage disputes, or renewal denials where you demonstrated required weight loss.
It varies by state. Humana operates Medicaid plans (Humana Healthy Horizons) in Florida, Illinois, Indiana, Kentucky, Louisiana, Ohio, Oklahoma, South Carolina and Virginia. 13 states (as of January 2026) cover GLP-1s for obesity under Medicaid. Contact your state's Humana Medicaid plan directly to verify current coverage and PA requirements.
If you have Humana Medicare, first check the Medicare GLP-1 Bridge ($50 per monthly fill, Zepbound KwikPen only). Otherwise your main options are: LillyDirect ($299–$449/month via the Zepbound Self Pay Journey; TrumpRx.gov lists the same prices), Foundayo (Lilly's oral GLP-1, $149–$299/month self-pay), or Walmart pharmacy pickup at LillyDirect pricing. The Lilly savings card won't help because it can't be used with Medicare or Medicaid.
WHAT'S COMING
Humana Coverage Outlook for 2026–2027
Humana's own plans still exclude weight loss, but federal programs now offer a separate route for Medicare members:
CMS BALANCE Model: GLP-1 Coverage Expansion
On December 23, 2025, CMS announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth)—a voluntary model to cover GLP-1s for weight loss in Medicare Part D and Medicaid.[9]
- Medicaid: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
- Medicare GLP-1 Bridge (separate program, live): July 1, 2026 – December 31, 2027 at $50 per monthly fill
- Medicare Part D: BALANCE is Delayed, with no new start date
Key point: Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization, so Humana Medicare members who meet CMS's criteria can use the Bridge whatever Humana decides.
What Stays the Same in 2026
- Basic Part D weight-loss exclusion still applies to Humana's own Medicare drug coverage (the Bridge runs outside the Part D benefit)
- OSA coverage continues for Medicare members under Humana's OSA policy (see the criteria above)
- Diagnosis code edits remain active for diabetes GLP-1s such as Ozempic and Mounjaro (claims with obesity codes reject)
For the latest Medicare policy details, see our Medicare coverage guide.
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
See how other insurers compare on Zepbound coverage:
- UnitedHealthcare — Depends on your employer’s plan; PA required where covered
- Blue Cross Blue Shield — Varies by Blue company; some (e.g., Massachusetts) dropped weight-loss coverage in 2026
- Cigna — Depends on your employer's plan; PA required (Cigna policy IP0816)
- Aetna — Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize) (Aetna's PBM); customized plans vary
- Medicare — Basic Part D coverage excludes weight-loss drugs; the Medicare GLP-1 Bridge can cover the Zepbound KwikPen, with conditions
References
- Humana. (2023, updated April 2024). "Reminder: Medically accepted indication edit." Provider notice listing Ozempic, Rybelsus, Trulicity, Victoza, Mounjaro and other drugs. humana.com
- FDA. (2024). "FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity." December 2024. fda.gov
- KFF. (2024). "Medicaid Coverage of and Spending on GLP-1s." kff.org
- Humana. (2025). "Zepbound (tirzepatide) Pharmacy Coverage Policy." Effective 1/20/2025; reviewed 7/15/2026; revised 7/22/2026. humana.com
- Eli Lilly. (2025). "Zepbound Prior Authorization Resource Guide." zepbound.lilly.com
- Humana. (2025). "Exception and Appeals Process Information." humana.com
- Eli Lilly. (2025). "Zepbound Self Pay Journey Program." LillyDirect pricing: $299/month (2.5mg), $399/month (5mg), $449/month (7.5-15mg). Updated December 2025. zepbound.lilly.com
- Walmart Corporate. (2025). "LillyDirect and Walmart Pharmacy Launch First Retail Pick-Up Option with Direct-to-Consumer Pricing for Zepbound." October 29, 2025 (single-dose vials; prices at launch have since changed). corporate.walmart.com
- CMS. (2025). "BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model." Announced December 23, 2025. Medicaid track voluntary for states; Part D track delayed by CMS with no new start date. cms.gov
Last updated October 6, 2026 · Key facts verified October 2, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.